The IDE Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted cell population generated from the human lung adenocarcinoma cell line NCI-H1975, featuring targeted ablation of the insulin-degrading enzyme (IDE) gene. This polyclonal knockout pool provides a loss-of-function model for investigating IDE’s roles in peptide hormone degradation and proteostasis within an epithelial cancer background. As a heterogeneous population, these cells retain the genetic diversity inherent to polyclonal editing, enabling robust and reproducible studies of IDE deficiency without clonal selection artifacts.
The parental NCI-H1975 cell line was originally derived from a female patient with non-small cell lung cancer and harbors well-characterized EGFR L858R/T790M activating mutations as well as a TP53 mutation. This line is widely utilized as a model of EGFR-mutant lung adenocarcinoma, allowing researchers to examine oncogenic signaling and therapeutic resistance mechanisms. Its epithelial origin and defined driver mutations make it particularly suitable for exploring crosstalk between metabolic pathways and cancer cell biology.
IDE encodes a zinc metalloprotease that primarily localizes to the cytosol and extracellular compartments, where it cleaves insulin, glucagon, amyloid-beta peptides, and other substrates. IDE’s catalytic activity is essential for terminating insulin signaling, clearing amyloid-beta aggregates, and maintaining peptide hormone homeostasis. Within the insulin signaling cascade, IDE functions downstream of insulin receptor activation and is regulated by insulin itself, as well as by PPAR?? and the PI3K/AKT pathway. IDE-mediated degradation of insulin limits the amplitude and duration of AKT phosphorylation, thereby attenuating downstream metabolic responses. Conversely, loss of IDE elevates insulin levels, enhancing signaling through the insulin receptor?CIRS?CPI3K?CAKT axis and promoting GLUT4 translocation. In neurodegenerative contexts, IDE reduces amyloid-beta accumulation, and its deficiency is linked to increased plaque formation via disrupted clearance.
In the NCI-H1975 lung adenocarcinoma model, IDE knockout introduces a unique tool for dissecting the interplay between insulin/IGF signaling and oncogenic pathways driven by EGFR mutations. Because NCI-H1975 cells rely on AKT-mediated survival and proliferation signals, IDE loss may potentiate insulin-stimulated AKT activation, potentially impacting tumor metabolism and growth. Furthermore, this knockout enables studies of amyloid-beta catabolism in an epithelial cancer context, expanding applications into neuroendocrine and metabolic syndrome research. The combination of EGFR-mutant cancer background with IDE deficiency thus provides a platform to explore how proteostatic and metabolic disruptions influence tumor behavior.
Researchers can employ this polyclonal knockout model in a wide array of functional assays. Western blotting and RT-qPCR confirm IDE ablation and transcript reduction, while Sanger sequencing detects insertions/deletions across the polyclonal population. Insulin degradation assays directly measure IDE enzymatic activity loss, and phospho-AKT analysis quantifies insulin signaling enhancement. Amyloid-beta ELISA enables assessment of peptide accumulation, and glucose uptake or cell proliferation assays reveal downstream metabolic consequences. These applications support investigations in cancer metabolism, diabetes, and Alzheimer’s disease modeling. For additional details or to inquire about this product, please contact Ascent Research.
